NPPA has increased the price of bare metal stents to Rs7,660 from Rs7,260 and reduced the price of drug-eluting and biodegradable stents to Rs27,890 from Rs29,600.
Amid safety concerns in the US, EU, Australia and India, the company has globally withdrawn two of its stents which it had marketed as innovative.
The policy proposes changes in the role and function of the National Pharmaceutical Pricing Authority, as well as to its overall structure, which will weaken the autonomy of the body.
The policy proposes a reversal to “monitoring” the prices of drugs, instead of “controlling” them, although the Supreme Court had earlier ruled against this.
The National Pharmaceutical Pricing Authority has capped the price of widely-used Cromium Cobalt knee implants at Rs 54,720.
The Centre’s pharmaceutical pricing agency has issued a demand-notice for Rs 1,26,547 from a Haryana hospital, which sources say is the first of many more recoveries.